Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
28 Feb 2017 EMA Recommends Extensions of Indication for Daratumumab Haematologic malignancies - Anticancer agents & Biologic therapy
27 Feb 2017 EMA Recommends Extensions of Indications for Dabrafenib and Trametinib Lung and other thoracic tumours - Anticancer agents & Biologic therapy
24 Feb 2017 FDA Approves Lenalidomide as Maintenance Therapy for Patients with Multiple Myeloma Following Autologous Stem Cell Transplant Haematologic malignancies - Anticancer agents & Biologic therapy
23 Feb 2017 NICE Issues Diagnostics Guidance on Molecular Testing Strategies for Lynch Syndrome in Patients with Colorectal Cancer Pathology/Molecular biology - Gastrointestinal cancers
22 Feb 2017 First Comprehensive Paediatric Haematology-Oncology Initiative Launched in Africa Bioethics, legal and economic issues - Cancer in Special Situations - Haematologic malignancies
21 Feb 2017 Phase II Study Supports Potential for Atezolizumab plus Bevacizumab for Locally Advanced or Metastatic Renal Cell Carcinoma Genitourinary cancers - Cancer Immunology and Immunotherapy - Anticancer agents & Biologic therapy
20 Feb 2017 FDA Accepts Two sBLAs for Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer in Cisplatin-Ineligible First-Line and Second-Line Post-Platinum Failure Treatment Settings Genitourinary cancers - Cancer Immunology and Immunotherapy - Anticancer agents & Biologic therapy
16 Feb 2017 EU Maltese Presidency on Fairer Pricing for Cancer Drugs Bioethics, legal and economic issues
15 Feb 2017 First-Line Treatment of EGFR and ALK Wild-Type Advanced/Metastatic NSCLC: Refined Endpoints and Statistical Analysis Plan in the Phase III MYSTIC Study Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
14 Feb 2017 European Patent Office Decision on Dasatinib Haematologic malignancies - Anticancer agents & Biologic therapy
13 Feb 2017 European Commission Approves Pembrolizumab for First-Line Treatment of Patients with Metastatic NSCLC Whose Tumours Have High PD-L1 Expression with No EGFR or ALK Positive Tumour Mutations Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
10 Feb 2017 Launch of the New Cobas m 511 Analyser Marks a New Era in Haematology Testing Haematologic malignancies
07 Feb 2017 Withdrawal of the Marketing Authorisation Application for Zioxtenzo (Pegfilgrastim) Palliative and supportive care
06 Feb 2017 EMA Recommends Granting a Marketing Authorisation for Hybrid Methotrexate Haematologic malignancies - Anticancer agents & Biologic therapy
03 Feb 2017 FDA Grants Accelerated Approval to Nivolumab for Treatment of Advanced Urothelial Carcinoma Genitourinary cancers - Cancer Immunology and Immunotherapy